KNSA

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: AMGN REGN BIIB VRTX GILD INCY BMRN NBIX EXEL SAGE

| Held by: VTI VB VBK VHT FESM DFAS DFAC SFLO EES ONEQ

Index	-	P/E	902.68	EPS (ttm)	0.04	Insider Own	43.95%	Shs Outstand	43.40M	Perf Week	3.89%
Market Cap	2.75B	Forward P/E	22.40	EPS next Y	1.66	Insider Trans	-3.41%	Shs Float	41.54M	Perf Month	10.25%
Enterprise Value	2.45B	PEG	-	EPS next Q	0.33	Inst Own	54.20%	Short Float	6.52%	Perf Quarter	33.79%
Income	4.79M	P/S	5.19	EPS this Y	283.54%	Inst Trans	-0.30%	Short Ratio	3.68	Perf Half Y	67.42%
Sales	529.33M	P/B	5.55	EPS next Y	50.41%	ROA	0.80%	Short Interest	2.71M	Perf YTD	87.56%
Book/sh	6.69	P/C	8.93	EPS next 5Y	-	ROE	1.03%	52W High	37.25 -0.40%	Perf Year	53.75%
Cash/sh	4.15	P/FCF	41.35	EPS past 3/5Y	35.96% 27.38%	ROIC	0.95%	52W Low	17.82 108.19%	Perf 3Y	220.93%
Dividend Est.	-	EV/EBITDA	409.93	Sales past 3/5Y	122.27% -	Gross Margin	53.07%	Volatility	3.26% 2.65%	Perf 5Y	141.38%
Dividend TTM	-	EV/Sales	4.63	EPS Y/Y TTM	141.87%	Oper. Margin	0.85%	ATR (14)	1.01	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.16	Sales Y/Y TTM	56.18%	Profit Margin	0.90%	RSI (14)	73.54	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.57	EPS Q/Q	516.00%	SMA20	7.10%	Beta	0.14	Target Price	46.50
Payout	-	Debt/Eq	0.02	Sales Q/Q	44.34%	SMA50	16.85%	Rel Volume	0.54	Prev Close	37.01
Employees	315	LT Debt/Eq	0.01	Earnings	Jul 29 BMO	SMA200	48.48%	Avg Volume	736.06K	Price	37.10
IPO	May 24, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.45% 7.04%	Trades		Volume	395,965	Change	0.24%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	Citigroup	Buy	$40
Sep-13-24	Initiated	Jefferies	Buy	$40
May-03-24	Initiated	Wells Fargo	Overweight	$34
Jun-29-20	Reiterated	BofA Securities	Buy	$25 → $40
Apr-01-20	Initiated	BofA/Merrill	Buy	$25
Mar-11-19	Initiated	Barclays	Overweight	$26
Dec-12-18	Reiterated	Wedbush	Outperform	$31 → $33
Jun-19-18	Initiated	JMP Securities	Mkt Outperform	$33

Sep-12-25 11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
Sep-04-25 11:06AM	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results (Zacks)
Sep-03-25 10:02AM	Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results (Zacks)
09:49AM	Loading…
09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
08:50AM	Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why (Zacks)
Sep-02-25 09:02AM	Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA? (Zacks)
Sep-01-25 10:50AM	ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win (Zacks)
Aug-29-25 10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks)
Aug-28-25 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)
Aug-26-25 11:16AM	Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin (Zacks)
Aug-25-25 11:04AM	PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug (Zacks)
Aug-18-25 09:55AM	Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade (Zacks)
08:50AM	Loading…
08:50AM	Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Aug-14-25 09:08AM	Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas (Zacks)
Aug-13-25 12:31PM	Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
07:39AM	5 Stocks With Recent Price Strength Amid Trade & Rate Cut Uncertainties (Zacks)
Aug-05-25 12:00PM	Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know (Zacks)
Aug-01-25 01:32PM	Just The Tonic: This Medical Stock, A Mutual Fund Darling, Tests Entry Amid 58% Run (Investor's Business Daily) +5.68%
12:20PM	Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge (Zacks)
09:55AM	Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect? (Zacks)
08:50AM	Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going (Zacks)
Jul-30-25 03:11AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... (GuruFocus.com)
Jul-29-25 08:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates (Zacks) +12.32%
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-28-25 09:29AM	Earnings To Watch: Kiniksa Pharmaceuticals International PLC (KNSA) Reports Q2 2025 Result (GuruFocus.com)
Jul-24-25 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 (GlobeNewswire)
Jul-03-25 08:42AM	Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore (Zacks)
07:00PM	Loading…
Jul-02-25 07:00PM	Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth (Motley Fool)
09:28AM	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment (Zacks)
Jul-01-25 01:38PM	Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong Tailwind (Investor's Business Daily)
01:37PM	Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind (Investor's Business Daily)
Jun-05-25 07:00AM	Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis (GlobeNewswire)
May-29-25 04:01PM	Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-05-25 04:51PM	Kiniksa Pharmaceuticals: Making Steady Progress (Seeking Alpha)
Apr-30-25 08:30AM	Kiniksa Pharmaceuticals Announces GRAMMY Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis (GlobeNewswire)
Apr-29-25 03:07PM	Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript (Seeking Alpha) +20.54%
08:35AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution (GlobeNewswire)
02:10AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everything You Need To Know Ahead Of ... (GuruFocus.com)
02:10AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-24-25 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 (GlobeNewswire)
Apr-22-25 07:21AM	Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
Apr-21-25 09:54AM	uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? (Zacks)
Apr-10-25 09:31AM	Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar? (Zacks) -6.28%
Apr-08-25 09:40AM	Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-04-25 09:55AM	Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know (Zacks) -6.43%
Mar-27-25 08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-19-25 09:55AM	How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6% (Zacks)
Mar-14-25 05:51AM	3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now (Motley Fool)
Mar-06-25 08:23AM	Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now? (Insider Monkey)
Mar-04-25 12:20PM	Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock (Zacks)
03:05AM	Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock? (Zacks)
Mar-03-25 09:55AM	Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High? (Zacks) +5.82%
Mar-02-25 11:58AM	Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-25-25 08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
07:29AM	Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy (GlobeNewswire)
Feb-20-25 04:01PM	Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (GlobeNewswire)
Feb-10-25 10:32AM	Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles (The Wall Street Journal)
Jan-13-25 07:30AM	Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance (GlobeNewswire) -8.83%
Jan-06-25 04:01PM	Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-26-24 04:01PM	Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-13-24 10:45AM	Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025? (Insider Monkey)
Nov-12-24 04:01PM	Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-30-24 04:25AM	Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ... (GuruFocus.com)
Oct-29-24 08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -15.68%
07:30AM	Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Oct-28-24 09:05AM	What To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings (GuruFocus.com)
08:00AM	Kiniksa Pharmaceuticals Partners with GRAMMY Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted Campaign to Drive Awareness of Recurrent Pericarditis (GlobeNewswire)
Oct-22-24 04:01PM	Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 (GlobeNewswire)
Oct-09-24 09:55AM	Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet (Zacks)
Oct-08-24 09:10PM	Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals (GuruFocus.com)
Oct-01-24 08:00AM	NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted Campaign to Drive Awareness of Recurrent Pericarditis (GlobeNewswire)
Aug-28-24 04:01PM	Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-05-24 09:55AM	Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade (Zacks)
Jul-26-24 12:00PM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know (Zacks)
08:50AM	Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why (Zacks)
Jul-23-24 08:35AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +22.91%
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-16-24 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024 (GlobeNewswire)
Jul-09-24 08:00AM	Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjogren's Disease (GlobeNewswire)
08:00AM	Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sj gren's Disease (GlobeNewswire)
Jun-24-24 08:00AM	Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis (GlobeNewswire)
Jun-17-24 08:30AM	Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative (GlobeNewswire)
Jun-04-24 04:01PM	Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 07:00AM	Sector Spotlight: Orphan Drug Developers With Significant Upside (News Direct)
May-07-24 04:01PM	Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
Apr-24-24 09:00AM	Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-23-24 11:53AM	KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:53AM	Kiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue Forecasts (GuruFocus.com)
08:40AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:36AM	Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises (MT Newswires)
07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Apr-16-24 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024 (GlobeNewswire)
Apr-02-24 07:30AM	Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart (GlobeNewswire)
Mar-01-24 09:55AM	Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect? (Zacks)

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tessari Eben	CHIEF OPERATING OFFICER	Sep 04 '25	Option Exercise	15.51	85,271	1,322,631	129,723	Sep 08 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 05 '25	Option Exercise	15.52	13,389	207,797	57,841	Sep 08 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 04 '25	Sale	35.52	85,271	3,028,826	44,452	Sep 08 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 05 '25	Sale	35.66	13,389	477,452	44,452	Sep 08 04:38 PM
Moat Ross	CHIEF CORP. & COMM. OFFICER	Sep 04 '25	Sale	35.31	3,523	124,397	9,415	Sep 08 04:37 PM
Tessari Eben	Officer	Sep 05 '25	Proposed Sale	35.66	13,389	477,497		Sep 05 04:39 PM
Tessari Eben	Officer	Sep 04 '25	Proposed Sale	35.52	85,271	3,028,740		Sep 04 04:52 PM
Moat Ross	Officer	Sep 04 '25	Proposed Sale	35.31	3,523	124,397		Sep 04 04:51 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 03 '25	Option Exercise	15.50	15,091	233,912	59,543	Sep 03 05:31 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 03 '25	Sale	35.50	15,091	535,730	44,452	Sep 03 05:31 PM
Tessari Eben	Officer	Sep 03 '25	Proposed Sale	35.50	15,091	535,778		Sep 03 04:56 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Sep 03 '25	Option Exercise	17.92	11,000	197,120	49,011	Sep 03 04:56 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Sep 03 '25	Sale	34.84	11,000	383,240	38,011	Sep 03 04:56 PM
Megna Michael R	Officer	Sep 03 '25	Proposed Sale	34.84	11,000	383,203		Sep 03 04:16 PM
Tessari Eben	CHIEF OPERATING OFFICER	Aug 18 '25	Option Exercise	8.83	6,500	57,395	56,415	Aug 20 04:36 PM
Tessari Eben	CHIEF OPERATING OFFICER	Aug 18 '25	Sale	33.77	16,200	547,141	40,215	Aug 20 04:36 PM
Tessari Eben	Officer	Aug 18 '25	Proposed Sale	33.77	16,200	547,070		Aug 18 05:13 PM
Malley Thomas	Director	Aug 14 '25	Option Exercise	14.89	78,233	1,165,028	90,779	Aug 14 04:59 PM
Malley Thomas	Director	Aug 13 '25	Option Exercise	10.07	50,129	504,936	62,675	Aug 14 04:59 PM
Malley Thomas	Director	Aug 12 '25	Option Exercise	2.94	49,407	145,146	61,953	Aug 14 04:59 PM
Malley Thomas	Director	Aug 14 '25	Sale	33.09	78,233	2,588,730	12,546	Aug 14 04:59 PM
Malley Thomas	Director	Aug 13 '25	Sale	33.32	50,129	1,670,298	12,546	Aug 14 04:59 PM
Malley Thomas	Director	Aug 12 '25	Sale	32.40	49,407	1,600,787	12,546	Aug 14 04:59 PM
Malley Thomas	Director	Aug 14 '25	Proposed Sale	33.09	78,233	2,588,711		Aug 14 04:36 PM
Malley Thomas	Director	Aug 13 '25	Proposed Sale	33.32	50,129	1,670,468		Aug 13 04:24 PM
Malley Thomas	Director	Aug 12 '25	Proposed Sale	32.40	49,407	1,600,641		Aug 12 04:54 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Aug 06 '25	Option Exercise	3.80	29,325	111,435	86,728	Aug 08 04:35 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Aug 06 '25	Sale	32.55	29,325	954,529	57,403	Aug 08 04:35 PM
Tessari Eben	CHIEF OPERATING OFFICER	Aug 05 '25	Option Exercise	11.44	138,614	1,585,652	188,529	Aug 07 04:40 PM
Tessari Eben	CHIEF OPERATING OFFICER	Aug 05 '25	Sale	33.20	138,614	4,602,370	49,915	Aug 07 04:40 PM
Paolini John F.	Officer	Aug 06 '25	Proposed Sale	32.55	29,325	954,476		Aug 06 05:37 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Aug 04 '25	Option Exercise	22.89	18,889	432,369	45,898	Aug 06 04:30 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Aug 04 '25	Sale	32.89	18,889	621,259	27,009	Aug 06 04:30 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Aug 04 '25	Option Exercise	15.52	17,000	263,840	50,041	Aug 06 04:30 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Aug 04 '25	Sale	32.35	17,000	549,950	33,041	Aug 06 04:30 PM
Tessari Eben	Officer	Aug 05 '25	Proposed Sale	33.20	138,614	4,602,409		Aug 05 05:23 PM
Ragosa Mark	Officer	Aug 04 '25	Proposed Sale	32.89	18,889	621,259		Aug 04 04:09 PM
Megna Michael R	Officer	Aug 04 '25	Proposed Sale	32.35	17,000	549,936		Aug 04 04:09 PM
Popovits Kimberly J	Director	Jul 30 '25	Option Exercise	11.85	64,508	764,166	77,054	Aug 01 04:36 PM
KIMBERLY J. POPOVITS	Director	Jul 30 '25	Proposed Sale	29.90	64,508	1,928,596		Jul 30 04:06 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jul 14 '25	Option Exercise	8.83	6,500	57,395	68,063	Jul 16 04:30 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jul 14 '25	Sale	28.72	18,900	542,808	49,163	Jul 16 04:30 PM
Tessari Eben	Officer	Jul 14 '25	Proposed Sale	28.72	18,900	542,860		Jul 14 05:04 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 16 '25	Option Exercise	8.83	6,500	57,395	78,863	Jun 18 04:39 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 16 '25	Sale	28.28	17,300	489,244	61,563	Jun 18 04:39 PM
Tessari Eben	Officer	Jun 16 '25	Proposed Sale	28.28	17,300	489,171		Jun 16 05:23 PM
Quart Barry D	Director	Jun 11 '25	Option Exercise	3.80	12,336	46,877	24,882	Jun 11 05:35 PM
Quart Barry D	Director	Jun 10 '25	Option Exercise	3.80	8,212	31,206	20,758	Jun 11 05:35 PM
Quart Barry D	Director	Jun 09 '25	Option Exercise	3.80	6,900	26,220	19,446	Jun 11 05:35 PM
Quart Barry D	Director	Jun 11 '25	Sale	30.39	12,336	374,891	12,546	Jun 11 05:35 PM
Quart Barry D	Director	Jun 10 '25	Sale	30.36	8,212	249,316	12,546	Jun 11 05:35 PM
Quart Barry D	Director	Jun 09 '25	Sale	30.26	6,900	208,794	12,546	Jun 11 05:35 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 11 '25	Option Exercise	10.36	45,042	466,635	117,405	Jun 11 05:32 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 10 '25	Option Exercise	10.36	15,506	160,642	87,869	Jun 11 05:32 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 09 '25	Option Exercise	10.36	10,319	106,905	82,682	Jun 11 05:32 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 11 '25	Sale	30.51	45,042	1,374,231	72,363	Jun 11 05:32 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 10 '25	Sale	30.46	15,506	472,313	72,363	Jun 11 05:32 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jun 09 '25	Sale	30.38	10,319	313,491	72,363	Jun 11 05:32 PM
Tessari Eben	Officer	Jun 11 '25	Proposed Sale	30.51	45,042	1,374,277		Jun 11 04:39 PM
Tessari Eben	Officer	Jun 10 '25	Proposed Sale	30.46	15,506	472,239		Jun 10 05:46 PM
Tessari Eben	Officer	Jun 09 '25	Proposed Sale	30.38	10,319	313,453		Jun 09 05:09 PM
Quart Barry D	Director	Jun 09 '25	Proposed Sale	30.26	27,448	830,576		Jun 09 05:08 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Jun 03 '25	Option Exercise	15.50	15,211	235,770	47,757	Jun 05 04:50 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Jun 03 '25	Sale	28.75	15,211	437,316	32,546	Jun 05 04:50 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Jun 03 '25	Option Exercise	13.35	27,594	368,380	37,009	Jun 05 04:46 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Jun 03 '25	Sale	29.02	27,594	800,778	9,415	Jun 05 04:46 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jun 03 '25	Option Exercise	18.00	18,299	329,382	45,308	Jun 05 04:38 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jun 03 '25	Sale	28.80	18,299	527,011	27,009	Jun 05 04:38 PM
Megna Michael R	Officer	Jun 03 '25	Proposed Sale	28.75	15,211	437,330		Jun 03 04:36 PM
Moat Ross	Officer	Jun 03 '25	Proposed Sale	29.02	27,594	800,914		Jun 03 04:35 PM
Ragosa Mark	Officer	Jun 03 '25	Proposed Sale	28.80	18,299	527,011		Jun 03 04:34 PM
Patel Sanj K	CHAIRMAN & CEO	May 28 '25	Option Exercise	1.59	62,116	98,764	158,790	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 27 '25	Option Exercise	1.59	19,317	30,714	115,991	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 23 '25	Option Exercise	1.59	4,837	7,691	101,511	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 28 '25	Sale	27.33	62,116	1,697,630	96,674	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 27 '25	Sale	27.01	19,317	521,752	96,674	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 23 '25	Sale	27.00	4,837	130,599	96,674	May 28 05:25 PM
Patel Sanj K	CHAIRMAN & CEO	May 20 '25	Option Exercise	1.59	2,349	3,735	99,023	May 22 04:38 PM
Patel Sanj K	CHAIRMAN & CEO	May 20 '25	Sale	27.02	2,349	63,470	96,674	May 22 04:38 PM
Tessari Eben	CHIEF OPERATING OFFICER	May 19 '25	Option Exercise	3.80	7,000	26,600	84,363	May 21 04:37 PM
Tessari Eben	CHIEF OPERATING OFFICER	May 19 '25	Sale	26.41	12,000	316,920	72,363	May 21 04:37 PM
Tessari Eben	Officer	May 19 '25	Proposed Sale	26.41	12,000	316,898		May 19 05:16 PM
Patel Sanj K	CHAIRMAN & CEO	May 13 '25	Option Exercise	1.59	2,872	4,566	99,546	May 15 04:39 PM
Patel Sanj K	CHAIRMAN & CEO	May 13 '25	Sale	27.03	2,872	77,630	96,674	May 15 04:39 PM
Patel Sanj K	CHAIRMAN & CEO	May 09 '25	Option Exercise	1.59	6,029	9,586	102,703	May 09 05:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 07 '25	Option Exercise	1.59	1,965	3,124	98,639	May 09 05:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 08 '25	Option Exercise	1.59	101	161	96,775	May 09 05:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 09 '25	Sale	27.05	6,029	163,084	96,674	May 09 05:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 07 '25	Sale	27.00	1,965	53,055	96,674	May 09 05:32 PM
Patel Sanj K	CHAIRMAN & CEO	May 08 '25	Sale	27.00	101	2,727	96,674	May 09 05:32 PM
Paolini John F.	CHIEF MEDICAL OFFICER	May 07 '25	Option Exercise	3.80	200	760	57,603	May 09 05:01 PM
Paolini John F.	CHIEF MEDICAL OFFICER	May 07 '25	Sale	27.00	200	5,400	57,403	May 09 05:01 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	May 07 '25	Option Exercise	12.53	17,647	221,098	50,193	May 09 04:59 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	May 07 '25	Sale	26.69	17,647	470,998	32,546	May 09 04:59 PM
Patel Sanj K	Officer	May 07 '25	Proposed Sale	27.00	99,586	2,688,822		May 07 05:13 PM
Paolini John F.	Officer	May 07 '25	Proposed Sale	27.00	29,525	797,175		May 07 04:59 PM
Megna Michael R	Officer	May 07 '25	Proposed Sale	26.69	17,647	471,014		May 07 04:00 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	May 05 '25	Option Exercise	17.76	6,272	111,391	15,687	May 05 04:54 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	May 02 '25	Option Exercise	17.76	3,850	68,376	13,265	May 05 04:54 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	May 05 '25	Sale	28.00	6,272	175,616	9,415	May 05 04:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Kiniksa Pharmaceuticals International Plc

Upgrade your FINVIZ experience